Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects

Autor: Maren Lindner, Béatrice Pignolet, David Brassat, Petra Hundehege, Maria Eveslage, Melanie Eschborn, Johanna Breuer, Luisa Klotz, Karin Loser, Andreas Schulte-Mecklenbeck, Sven G. Meuth, Judith Austermann, Catharina C. Gross, Nicole Freise, Karin B. Busch, Nicholas Schwab, Giulia Nebel, Tilman Schneider-Hohendorf, Timothy J. Turner, Vilmos Posevitz, Heinz Wiendl, Marie Liebmann, Amit Bar-Or, Martin Herold, Shirin Glander, Belén Torres Garrido, Johannes Roth, Claudia Janoschka, Timo Wirth, Graham R. Campbell, Don J. Mahad, Monika Stoll

Publikováno v: Klotz, L, Eschborn, M, Lindner, M, Liebmann, M, Herold, M, Janoschka, C, Torres Garrido, B, Schulte-Mecklenbeck, A, Gross, C C, Breuer, J, Hundehege, P, Posevitz, V, Pignolet, B, Nebel, G, Glander, S, Freise, N, Austermann, J, Wirth, T, Campbell, G R, Schneider-Hohendorf, T, Eveslage, M, Brassat, D, Schwab, N, Loser, K, Roth, J, Busch, K B, Stoll, M, Mahad, D J, Meuth, S G, Turner, T, Bar-Or, A & Wiendl, H 2019, ' Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects ', Science Translational Medicine, vol. 11, no. 490, eaao5563 . https://doi.org/10.1126/scitranslmed.aao5563
Science Translational Medicine, 11(490):5563. American Association for the Advancement of Science
Science Translational Medicine
Science Translational Medicine, 2019, 11 (490), ⟨10.1126/scitranslmed.aao5563⟩

International audience; Interference with immune cell proliferation represents a successful treatment strategy in T cell-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (MS). One prominent example is pharmacological i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c6a6928d973af7c45bf548e65e0113
https://hdl.handle.net/20.500.11820/c76c0dcd-4614-4fdc-92e3-04332843a83f